0000358654
Donate

Reimbursement status:
Reimbursement with restrictions

Cancer: Multiple myeloma and plasma cell neoplasms

Indication:

Lenalidomide as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide as combination therapy is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L04AX
L04AX Other immunosuppressants
EMA approval status :
Approved
EMA approval date :
2007-06-14
EMA conditional? :
No
EMA orphan? :
Yes
EMA biological? :
No